… cohort of molnupiravir-treated immunocompromised participants were not at unique locations
compared to molnupiravir- or placebo-treated non-immunocompromised participants. This …

… We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, …

… and treatment approaches in immunocompromised people … included very few
immunocompromised participants. While … care arm could even receive molnupiravir. Although no …

… -analysis (including 3 RCTs enrolling 1487 participants and 5 controlled studies) CCP was
… Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent …

… Molnupiravir was safe during the study period in outpatients although … routine use of
molnupiravir for COVID-19 treatment in … participants was only about 6% and 9% in molnupiravir …

… Conclusion: Molnupiravir may be perceived as an alternative treatment for patients with
immunosuppression … All the study participants completed a full course of molnupiravir treatment. …

… for molnupiravir, arguing that the available data did not demonstrate the clinical benefit of
molnupiravir in treating … for the treatment of COVID-19 in non-hospitalized participants is still …

… , with a reduction in CRP after antiviral treatment. In addition, in Johnson’s study of the safe
population, participants who received molnupiravir had earlier and larger reductions in mean …

… of molnupiravir and nirmatrelvir/r showed increased activity [10, 11], as did combined treatment
with molnupiravir … In the trial of early treatment with tixagevimab/cilgavimab, 4 participants …

… All participants in the trial were not vaccinated. … immunodeficiency mostly related to active
hematological disease and immunosuppressant treatment (49.3% in the molnupiravir group, …